Skip to main content
SpringerLink
Log in

Landmark and longitudinal exposure–response analyses in drug development

  • Commentary
  • Published:
Journal of Pharmacokinetics and Pharmacodynamics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Overgaard RV, Ingwersen SH, Tornoe CW (2015) Establishing good practices for exposure-response analysis of clinical endpoints in drug development. CPT 4(10):565–575. doi:10.1002/psp4.12015

    CAS  Google Scholar 

  2. Urquhart J (2002) History informed perspectives on modeling and simulation of drug therapeutic actions. In: Kimko HD (ed) Simulation for designing clinical trials: a pharmacokinetic-pharmacodynamic modeling perspective. CRC Press, Boca Raton

    Google Scholar 

  3. Sharma A, Jusko WJ (1996) Characterization of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 24(6):611–635

    Article  CAS  PubMed  Google Scholar 

  4. Krzyzanski W, Jusko WJ (1998) Integrated functions for four basic models of indirect pharmacodynamic response. J Pharm Sci 87(1):67–72. doi:10.1021/js970168r

    Article  CAS  PubMed  Google Scholar 

  5. Gabrielsson J, Hjorth S (2016) Pattern recognition in pharmacodynamic data analysis. AAPS J 18(1):64–91. doi:10.1208/s12248-015-9842-5

    Article  CAS  PubMed  Google Scholar 

  6. Hu C (2014) Exposure-response modeling of clinical end points using latent variable indirect response models. CPT 3:117. doi:10.1038/psp.2014.15

    Google Scholar 

  7. Hu C, Zhou H (2016) Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritis. J Pharmacokinet Pharmacodyn 43(1):45–54

    Article  PubMed  Google Scholar 

  8. Hu C, Xu Z, Mendelsohn A, Zhou H (2013) Latent variable indirect response modeling of categorical endpoints representing change from baseline. J Pharmacokinet Pharmacodyn 40(1):81–91

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Rebecca Zhou of Swarthmore College, Swarthmore, PA for her excellent editorial support.

Author information

Authors and Affiliations

  1. Global Clinical Pharmacology, Janssen Research & Development, LLC, PO Box 776, 1400 McKean Road, Spring House, PA, 19477, USA

    Chuanpu Hu, Honghui Zhou & Amarnath Sharma

Authors
  1. Chuanpu Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Honghui Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amarnath Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chuanpu Hu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hu, C., Zhou, H. & Sharma, A. Landmark and longitudinal exposure–response analyses in drug development. J Pharmacokinet Pharmacodyn 44, 503–507 (2017). https://doi.org/10.1007/s10928-017-9534-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10928-017-9534-0

Keywords

Search

Navigation